This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edelstein, P. H.
Right arrow Articles by Edelstein, M. A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edelstein, P. H.
Right arrow Articles by Edelstein, M. A. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2003, p. 533-540, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.533-540.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Activities of Tigecycline (GAR-936) against Legionella pneumophila In Vitro and in Guinea Pigs with L. pneumophila Pneumonia

Paul H. Edelstein,1,2* William J. Weiss,3 and Martha A. C. Edelstein1

Departments of Pathology and Laboratory Medicine,1 Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-4283,2 Wyeth Research, Pearl River, New York 109653

Received 28 May 2002/ Returned for modification 11 October 2002/ Accepted 13 November 2002

The activities of tigecycline (Wyeth Research) against extracellular and intracellular Legionella pneumophila and for the treatment of guinea pigs with L. pneumophila pneumonia were studied. The tigecycline MIC at which 50% of strains are inhibited for 101 different Legionella sp. strains was 4 µg/ml versus 0.125 and 0.25 µg/ml for azithromycin and erythromycin, respectively. Tigecycline was about as active as erythromycin (tested at 1 µg/ml) against the F889 strain of L. pneumophila grown in guinea pig alveolar macrophages and more active than erythromycin against the F2111 strain. Azithromycin (0.25 µg/ml) was more active than (F889) or as active as (F2111) tigecycline (1 µg/ml) in the macrophage model. When tigecycline was given (7.5 mg/kg of body weight subcutaneously once) to guinea pigs with L. pneumophila pneumonia, the mean peak serum and lung levels were 2.3 and 1.8 µg/ml (1.2 and 1.5 µg/g) at 1 and 2 h postinjection, respectively. The serum and lung areas under the concentration time curve from 0 to 24 h were 13.7 and 15.8 µg · h/ml, respectively. Thirteen of 16 guinea pigs with L. pneumophila pneumonia treated with tigecycline (7.5 mg/kg subcutaneously once daily for 5 days) survived for 7 days post-antimicrobial therapy, as did 11 of 12 guinea pigs treated with azithromycin (15 mg/kg intraperitoneally once daily for 2 days). None of 12 guinea pigs treated with saline survived. Tigecycline-treated guinea pigs had average end of therapy lung counts of 1 x 106 CFU/g (range, 2.5 x 104 to 3.2 x 106 CFU/g) versus <1 x 102 CFU/g for azithromycin (range, undetectable to 100 CFU/g). A second guinea pig study examined the ability of tigecycline to clear L. pneumophila from the lung after 5 to 9 days of therapy; bacterial concentrations 1 day posttherapy ranged from log10 4.2 to log10 5.5 CFU/g for four different dosing regimens. Tigecycline is about as effective as erythromycin against intracellular L. pneumophila, but tigecycline inactivation by the test media confounded the interpretation of susceptibility data. Tigecycline was effective at preventing death from pneumonia in an animal model of Legionnaires' disease, warranting human clinical trials of the drug for the disease.

* Corresponding author. Mailing address: Clinical Microbiology Laboratory, 4 Gates, Hospital of the University of Pennsylvania, 3400 Spruce St., Philadelphia, PA 19104-4283. Phone: (215) 662-6651. Fax: (215) 662-6655. E-mail: phe{at}mail.med.upenn.edu.

Antimicrobial Agents and Chemotherapy, February 2003, p. 533-540, Vol. 47, No. 2
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.2.533-540.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Spyridaki, I., Psaroulaki, A., Vranakis, I., Tselentis, Y., Gikas, A. (2009). Bacteriostatic and Bactericidal Activities of Tigecycline against Coxiella burnetii and Comparison with Those of Six Other Antibiotics. Antimicrob. Agents Chemother. 53: 2690-2692 [Abstract] [Full Text]  
  • Izdebski, R., Sadowy, E., Fiett, J., Grzesiowski, P., Gniadkowski, M., Hryniewicz, W. (2007). Clonal Diversity and Resistance Mechanisms in Tetracycline-Nonsusceptible Streptococcus pneumoniae Isolates in Poland. Antimicrob. Agents Chemother. 51: 1155-1163 [Abstract] [Full Text]  
  • Pankey, G. A. (2005). Tigecycline. J Antimicrob Chemother 56: 470-480 [Abstract] [Full Text]  
  • Edelstein, P. H., Hu, B., Edelstein, M. A. C. (2005). In Vitro and Intracellular Activities of LBM415 (NVP PDF-713) against Legionella pneumophila. Antimicrob. Agents Chemother. 49: 2533-2535 [Abstract] [Full Text]  
  • Muralidharan, G., Fruncillo, R. J., Micalizzi, M., Raible, D. G., Troy, S. M. (2005). Effects of Age and Sex on Single-Dose Pharmacokinetics of Tigecycline in Healthy Subjects. Antimicrob. Agents Chemother. 49: 1656-1659 [Abstract] [Full Text]  
  • Muralidharan, G., Micalizzi, M., Speth, J., Raible, D., Troy, S. (2005). Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects. Antimicrob. Agents Chemother. 49: 220-229 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»